Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Transcriptional regulatory effects of lymphoma-associated NFKB2/lyt10 protooncogenes

Oncogene volume 19, pages 1334–1345 (2000)Cite this article

Abstract

C-terminal truncations of the NFKB2 p100 gene product have been observed in a number of cases of human cutaneous T cell lymphomas, as well as human B-cell lymphomas and myelomas. The contribution of these alterations to lymphomagenesis is not understood; however, truncation at amino acid 666 to generate 80–85 kD proteins in the HUT78 cell line is associated with addition of a short (serine-alanine-serine) fusion at the 3′ end of p80HT, as well as with increased expression of NFKB2 mRNA. We therefore examined the effects of p80HT on the regulation of NFKB2 expression, as well as the properties of a series of other tumor-associated, and site directed mutations of NFKB2. While p80HT had not itself acquired novel transcriptional activation properties with respect to the NFKB2 P1 or P2 promoters or the IL-6 κB promoter, p80HT had lost the potent inhibitory (IκB-like) activity associated with the wild-type, p100 gene product. Loss of the inhibitory property depended on the SAS residues in the fusion protein, direct truncation at aa666 was fully inhibitory, as was a substitution of three alanines for the SAS residues. The presence of as few as two C-terminal ankyrin motifs was sufficient for inhibition of NF-κB-mediated transcriptional activation. Assays of a series of additional lymphoma-associated NF-κB-2 truncation suggested that the C-terminal truncation associated with these proteins was also associated with a loss of the IκB-like activities of p100 NF-κB-2, for at least some NF-κB target promoters. Thus, the loss of IκB-like activity of lymphoma-associated NFKB2 mutations may play an important role in the genesis of a subset of human lymphomas.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  • Baeuerle PA and Baltimore D . 1988 Cell 53: 211–217

  • Baeuerle PA and Baltimore D . 1989 Genes Dev 3: 1689–1698

  • Baldwin Jr AS . 1996 Annu Rev Immunol 14: 649–683

  • Beauparlant P, Kwan I, Bitar R, Chou P, Koromilas AE, Sonenberg N and Hiscott J . 1994 Oncogene 9: 3189–3197

  • Beg AA and Baltimore D . 1996 Science 274: 782–787

  • Belich MP, Salmeron A, Johnston LH and Ley SC . 1999 Nature 397: 363–368

  • Betts J and Nabel GJ . 1996 Mol Cell Biol 16: 6363–6371

  • Blake TJ and Langdon WY . 1992 Oncogene 7: 757–762

  • Blank V, Kourilsky P and Israel A . 1991 EMBO J 10: 4159–4167

  • Bours V, Burd PR, Brown K, Villalobos J, Park S, Ryseck R-P, Bravo R, Kelly K and Siebenlist U . 1992 Mol Cell Biol 12: 685–695

  • Bradford MM . 1976 Anal Biochem 72: 248–264

  • Cabannes E, Khan G, Aillet F, Jarrett RF and Hay RT . 1999 Oncogene 18: 3063–3070

  • Chang CC, Zhang J, Lombardi L, Neri A and Dalla-Favera R . 1995 Mol Cell Biol 15: 5180–5187

  • Ciana P, Neri A, Cappellini C, Cavallo F, Pomati M, Chang CC, Maiolo AT and Lombardi L . 1997 Oncogene 14: 1805–1810

  • Dejardin E, Deregowski V, Chapelier M, Jacobs N, Gielen J, Merville MP, Bours V . 1999 Oncogene 18: 2567–2577

  • DiDonato JA, Hayakawa M, Rothwarf DM, Zandi E and Karin M . 1997 Nature 388: 548–554

  • Finger LR, Huebner K, Cannizarro LA, McLeod K, Nowell PC and Croce CM . 1988 Proc Natl Acad Sci USA 85: 9158–9162

  • Fracchiolla NS, Lombardi L, Salina M, Migliazza A, Baldini L, Berti E, Cro L, Polli E, Maiolo AT and Neri A . 1993 Oncogene 8: 2839–2845

  • Franzoso G, Bours V, Park S, Tomita-Yamaguchi M, Kelly K and Siebenlist U . 1992 Nature London 359: 339–342

  • Fujita T, Nolan GP, Ghosh S and Baltimore D . 1992 Genes Dev 6: 775–787

  • Gerondakis S, Grumont R, Rourke I and Grossmann M . 1998 Curr Opin Immunol 10: 353–359

  • Ghosh S, May MJ and Kopp EB . 1998 Ann Rev Immunol 16: 225–260

  • Gilmore TD, Koedood M, Piffat KA and White DW . 1996 Oncogene 13: 1367–1378

  • Gorman CM, Moffat LF and Howard BH . 1982 Mol Cell Biol 2: 1044–1051

  • Graham FL and Van der Eb AJ . 1973 Virol 52: 456–457

  • Hatada EN, Naumann M and Scheidereit C . 1993 EMBO J 12: 2781–2788

  • Henkel T, Zabel U, Van Zee K, Muller JM, Arnold GJ, Fanning E and Baeuerle P . 1992 Cell 68: 1121–1133

  • Heusch M, Lin L, Geleziunas R and Greene WC . 1999 Oncogene 18: 6201–6208

  • Huxford T, Huang DB, Malek S and Ghosh G . 1998 Cell 95: 759–770

  • Inoue J, Kerr LD, Rashid D, Davis N, Bose HRJ and Verma IM . 1992 Proc Natl Acad Sci USA 89: 4333–4337

  • Ishikawa H, Carrasco D, Claudio E, Ryseck R-P and Bravo R . 1997 J Exp Med 186: 999–1014

  • Jacobs MD and Harrison SC . 1998 Cell 95: 749–758

  • Jaffray E, Wood KM and Hay R . 1995 Mol Cell Biol 15: 2166–2172

  • Kanno T, Franzoso G and Siebenlist U . 1994 Proc Natl Acad Sci USA 91: 12634–12638

  • Kopp EB and Ghosh S . 1995 Adv Immunol 58: 1–27

  • Krappmann D, Emmerich F, Kordes U, Scharschmidt E, Dorken B and Scheidereit C . 1999 Oncogene 18: 943–953

  • Lin L, DeMartino GN and Greene WC . 1998 Cell 92: 819–828

  • Lin L and Ghosh S . 1996 Mol Cell Biol 16: 2248–2254

  • Liptay S, Schmid RM, Nabel EG and Nabel GJ . 1994 Mol Cell Biol 14: 7695–7703

  • Liu ZG, Hsu H, Goeddel DV and Karin M . 1996 Cell 87: 565–576

  • Lombardi L, Ciana P, Cappellini C, Trecca D, Guerrini L, Migliazza A, Maiolo AT and Neri A . 1995 Nucleic Acids Res 23: 2328–2336

  • Luque I and Gélinas C . 1977 Sem Cancer Biol 8: 103–111

  • Luque I and Gélinas C . 1998 Mol Cell Biol 18: 1213–1224

  • Malek S, Huxford T and Ghosh G . 1998 J Biol Chem 273: 25427–25435

  • Martin MA, Bryan T, Rasheed S and Khan AS . 1981 Proc Natl Acad Sci USA 78: 4892–4896

  • May MJ and Ghosh S . 1997 Sem Cancer Biol 8: 63–73

  • May MJ and Ghosh S . 1998 Immunol Today 19: 80–88

  • Mercurio F, DiDonato J, Rosette C and Karin M . 1992 DNA Cell Biol 11: 523–537

  • Mercurio F, Zhu H, Murray BW, Shevchenko A, Bennett BL, Li JW, Young DB, Barbosa M and Mann M . 1997 Science 278: 860–866

  • Migliazza A, Lombardi L, Rocchi M, Trecca D, Chang CC, Antonacci R, Fracchiolla NS, Ciana P, Maiolo AT and Neri A . 1994 Blood 84: 3850–3860

  • Nagatani T, Miyazawa M, Matsuzaki T, Iemoto G, Kim ST, Baba N, Miyamoto H and Nakajima H . 1994 Semin Dermatol 13: 216–222

  • Naumann M, Nieters A, Hatada EN and Scheidereit C . 1993a Oncogene 8: 2275–2281

  • Naumann M, Wulczyn FG and Scheidereit C . 1993b EMBO J 12: 213–222

  • Neri A, Chang C-C, Lombardi L, Salina M, Corradini P, Maiolo AT, Chaganti RSK and Dalla-Favera R . 1991 Cell 67: 1075–1087

  • Neri A, Fracchiolla NS, Migliazza A, Trecca D and Lombardi L . 1996 Leukemia Lymphoma 23: 43–48

  • Neri A, Fracchiolla NS, Roscetti E, Garatti S, Trecca D, Boletini A, Perletti I, Baldini L, Maiolo AT and Berti E . 1995 Blood 86: 3160–3172

  • Nielsen M, Kaltoft K, Nordahl M, Ropke C, Geisler C, Mustelin T, Dobson P, Svejgaard A and Odum N . 1997 Proc Natl Acad Sci USA 94: 6764–6769

  • Oswald R, Liptay S, Adler G and Schmid RM . 1998 Mol Cell Biol 18: 2077–2088

  • Palombella VJ, Rando OJ, Goldberg AL and Maniatis T . 1994 Cell 78: 773–785

  • Pan J and McEver RP . 1995 J Biol Chem 270: 23077–23083

  • Rayet B and Gélinas C . 1999 Oncogene 18: 6938–6947

  • Reginer CH, Song HY, Gao X, Goeddel DV, Cao Z and Rothe M . 1997 Cell 90: 373–383

  • Rice N, MacKichan ML and Israel A . 1992 Cell 71: 243–253

  • Ruben SM, Narayan R, Klement JF, Chen CH and Rosen CA . 1992 Mol Cell Biol 12: 444–454

  • Sanger F, Nicklen S and Coulson AR . 1997 Proc Natl Acad Sci USA 74: 5463–5467

  • Scheinman RI, Beg AA and Baldwin Jr AS . 1993 Mol Cell Biol 13: 6089–6101

  • Schmid RM, Perkins ND, Duckett CS, Andrews PC and Nabel G . 1991 Nature 352: 733–736

  • Shimizu H, Mitomo K, Watanabe T, Okamoto S and Yamamoto K . 1990 Mol Cell Biol 10: 561–568

  • Siebenlist U, Franzoso G and Brown K . 1994 Annu Rev Cell Biol 10: 405–455

  • Sonenshein GE . 1997 Sem Cancer Biol 8: 113–119

  • Thakur S, Lin H-C, Tseng W-T, Kumar S, Bravo R, Foss F, Gélinas C and Rabson AB . 1994 Oncogene 9: 2335–2344

  • Tolomeo M, Dusonchet L, Meli M, Grimaudo S, D'Alessandro N, Papoff G, Ruberti B and Rausa L . 1998 Cell Death Differ 5: 735–742

  • Van Antwerp DJ, Martin SJ, Kafri T, Green DR and Verma IM . 1996 Science 274: 787–789

  • Verma IM, Stevenson JK, Schwarz EM, Van Antwerp D and Miyamoto S . 1995 Genes Dev 9: 2723–2735

  • Wang CY, Mayo MW and Baldwin Jr AS . 1996 Science 274: 784–787

  • Wood KM, Roff M and Hay RT . 1998 Oncogene 16: 2131–2139

  • Zandi E and Karin M . 1999 Mol Cell Biol 19: 4547–4551

  • Zandi E, Rothwarf DM, Delhase M, Hayakawa M and Karin M . 1997 Cell 91: 243–252

  • Zhang J, Chang C-C, Lombardi L and Dalla-Favera R . 1994 Oncogene 9: 1931–1937

  • Zhang Q, Nowak I, Vonderheid EC, Rook AH, Kadin ME, Nowell PC, Shaw LM and Wasik MA . 1996 Proc Natl Acad Sci USA 93: 9148–9153

Download references

Acknowledgements

We thank Dr R Dalla Favera for the pHCMV lyt10Cα expression vector, Dr C Rosen for the RelA/p65 CMV expression vector, and Dr R McEver for the P-selectin luciferase reporter gene plasmid. We thank J Lee for assistance with plasmid preparations and screening, F Foss, F Payvandi, J Suh, A Ramakrishnan, C Chen, and W-X Zhang for helpful discussions, and Dr C Gélinas for suggestions and critical reading of the manuscript. This work was supported by National Institutes of Health, NCI grant CA 68333.

Author information

Author notes

  1. Kyoung-Eun Kim and Chunyan Gu: K-E Kim and C Gu contributed equally to this work

Authors and Affiliations

  1. Center for Advanced Biotechnology and Medicine, University of Medicine and Dentistry – Robert Wood Johnson Medical School, Piscataway, 08854, New Jersey, NJ, USA

    Kyoung-Eun Kim, Chunyan Gu, Sanjay Thakur, Eric Vieira, Jennifer C Lin & Arnold B Rabson

  2. Department of Molecular Genetics and Microbiology, University of Medicine and Dentistry – Robert Wood Johnson Medical School, Piscataway, 08854, New Jersey, NJ, USA

    Kyoung-Eun Kim, Chunyan Gu & Arnold B Rabson

  3. Cancer Institute of New Jersey, University of Medicine and Dentistry – Robert Wood Johnson Medical School, New Brunswick, 08901, New Jersey, NJ, USA

    Arnold B Rabson

Authors
  1. Kyoung-Eun Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Chunyan Gu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sanjay Thakur
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Eric Vieira
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jennifer C Lin
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Arnold B Rabson
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kim, KE., Gu, C., Thakur, S. et al. Transcriptional regulatory effects of lymphoma-associated NFKB2/lyt10 protooncogenes. Oncogene 19, 1334–1345 (2000). https://doi.org/10.1038/sj.onc.1203432

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1203432

Keywords

This article is cited by

Search

Advanced search

Quick links